/
CGEM
$18.42+$0.02 (+0.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
61M shares
52-week range
$5.68 – $19.43
93% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.48
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $18.9M | $0 | $0 | $0 | $0 |
| Cost of revenue | $43.0K | $70.0K | $62.0K | $0 | $0 | $0 | $306.0K | $0 |
| Gross profit | −$43.0K | −$70.0K | −$62.0K | $18.9M | $0 | $0 | −$306.0K | $0 |
| Gross margin | — | — | — | 100.0% | — | — | — | — |
| R&D | $9.6M | $16.8M | $43.2M | $57.8M | $91.9M | $148.2M | $142.9M | $187.4M |
| Operating income | −$14.6M | −$22.3M | −$60.3M | −$68.0M | $144.6M | −$191.1M | −$196.9M | −$241.6M |
| EBITDA | −$14.5M | −$22.2M | −$60.3M | −$67.4M | −$132.0M | −$190.3M | −$167.2M | −$219.6M |
| Net income | −$14.2M | −$20.0M | −$51.8M | −$65.6M | $111.2M | −$153.2M | −$167.4M | −$219.9M |
| Net margin | — | — | — | -346.1% | — | — | — | — |
| EPS (diluted) | -17.74 | -19.68 | -1.19 | -1.48 | 2.38 | -3.69 | -3.11 | -3.72 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $18M | $-3.03 | $-3.39–$-2.49 | 8 |
| 2027 | $48M | $-2.41 | $-3.13–$-1.38 | 7 |
| 2028 | $31M | $-2.99 | $-3.33–$-2.77 | 7 |
| 2029 | $70M | $-2.90 | $-4.37–$-1.42 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.44
Price
$18.42
Implied downside
-92%
Peer comparison
Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
www.cullinantherapeutics.com- Employees
- 109
- IPO / List date
- Jan 8, 2021
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds CGEM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 324,111 | $4.6M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2009-08-31 | 2-for-1 |
| 2009-03-04 | 6-for-1 |
Recent trades on TradeandTell
No one on the platform has traded CGEM yet.
